item management s discussion and analysis of financial condition and results of operations general emisphere is a drug delivery company focused on the discovery and application of proprietary synthetic chemical compounds that enable the oral delivery of macromolecules and other compounds that are not currently deliverable by oral means 
since its inception in  the company has devoted substantially all of its efforts and resources to research and development conducted on its own behalf and through c o l l aborations with corporate partners and academic research institutions 
the company has had no product sales to date 
the major sources of the company s working capital have been proceeds from its initial public offering in  a second public offering in february  private equity financing  the latest of which occurred in october  reimbursement of expenses and other payments from corporate partners  the registered sale of one million shares of common stock to two institutional investors in april  and income earned on the investment of available funds 
the company s operations are not significantly affected by inflation or seasonality 
results of operations the company has since its inception generated significant losses from operations 
the company does not expect to achieve profitability in the foreseeable future 
profitability will ultimately depend on the company s ability to develop its lead product  an oral formulation of heparin  in conjunction with the elan joint venture or to develop other products in conjunction with other partners 
there can be no assurance that the development will be completed or if completed  any regulatory agency will approve the final product 
even if final products are developed and approved  there is no assurance that sales will be sufficient to achieve profitability 
if development of such products is not achieved or approval not granted  the company s prospects will be materially affected 
the ability of the company to reduce its operating losses in the near term will be dependent upon  among other things  its ability to attract new pharmaceutical and other companies who are willing to provide funding to the company for a portion of the company s research and development with respect to specific projects 
while the company is constantly engaged in discussions with pharmaceutical and other companies  there can be no assurance that the company will enter into any additional agreements or that the agreements will provide research and development revenues to the company 
fiscal compared to fiscal revenue increased by approximately  the revenue consisted of a payment of  from elan to reimburse the company for certain research and development costs  and payments from two other pharmaceutical companies for which the company performed feasibility studies 
the recognition of the revenue from elan was for work emisphere performed on development of an oral formulation of heparin 
total operating expenses for the fiscal year ended july  increased by approximately  or  as compared to fiscal the details of the increase are as follows r e search and development costs increased by approximately  or  in fiscal as compared to fiscal the increase is mainly attributable to the company s clinical development program for heparin 
the clinical development program consisted of work performed to file an investigational new drug application ind application with the fda for the commencement of a phase i clinical t r ial  and the performance of a double blind controlled dose escalation study in humans  as well as other studies undertaken to support the development of an oral formulation of heparin 
the higher costs associated with the clinical development program relating to heparin were partially offset by a decrease in funding of outside consultants and universities  not associated with the clinical program  engaged to conduct studies to help advance the company s scientific research efforts 
the company also experienced a decrease in personnel and related expenses due  in part  to a staff reduction in may the company believes that this level of research and development spending will continue for the foreseeable future and may increase if operations are expanded 
general and administrative expenses increased by approximately  or  in fiscal as compared to fiscal this increase is primarily attributable to an increase in expenses relating to services provided by outside business consultants 
the company recorded expenses of approximately  in connection with the granting of stock and options as compensation to business consultants for assisting the company in discussions and negotiations with pharmaceutical companies 
the company also experienced an increase in legal and other professional fees incurred in connection with  among other things  the settlement of a class action lawsuit and the elan joint venture 
as a result of these factors  the company s operating loss decreased by approximately  or  from fiscal to fiscal the company does not expect to generate an operating profit  and may possibly generate larger operating losses  in the foreseeable future 
t h e company s other income for fiscal increased by approximately  or  from fiscal this was primarily due to a larger investment portfolio as a result of recent equity financing and research and development revenues of  received from elan 
based on the above  the company s net loss for fiscal was  a decrease over fiscal s loss of  fiscal compared to fiscal revenue decreased by approximately  or 
the revenues consisted of an initial payment under the company s agreement with pasteur merieux to study the applicability of one of the company s drug delivery technologies for the delivery of a flu antigen 
there were no other revenues during fiscal from the company s other partners under their respective agreements with the company 
in comparison  fiscal revenues consisted of a final payment under the company s agreement with sandoz pharmaceutical corporation 
total operating expenses for the fiscal year ended july  decreased by  or  as compared to fiscal the details of the decrease are as follows research and development costs decreased by approximately  or  in fiscal as compared to fiscal the reduced cost was attributable to decreased funding of outside consultants and universities engaged to conduct studies to help advance the company s scientific research effort and a decrease in usage of laboratory supplies as a result of a reduction in the number of projects on which the company was actively working 
the reduction was partially offset by an increase in personnel and related expenses during the first ten months of the year  as the company pursued its c l inical development program for oral heparin 
in addition  depreciation and amortization expense increased by approximately  in fiscal  resulting from purchases of laboratory equipment and furniture placed in service subsequent to july  general and administrative expenses decreased by approximately  or  in fiscal as compared to fiscal the decrease in expenses was attributable to a decrease in personnel and related expenses due  in part  to a staff reduction in may  reduced payments to outside consultants engaged as financial advisors w h o se purpose was to assist the company in discussions and negotiations  and a decrease in supplies purchased during the fiscal year 
the reduction was partially offset by an increase in insurance costs for directors and officers insurance and for protection of the company s assets  and professional fees paid to seek patent protection for the company s proprietary inventions 
as a result of these factors  the company s operating loss decreased by approximately  or  from fiscal to fiscal t h e company s other income for fiscal decreased by approximately  or  from fiscal this was primarily the result of net losses of approximately  incurred on the sale of marketable securities and decreased interest income on the company s smaller investment portfolio as the company expended funds on operations and fixed asset additions 
also included in other income in fiscal was collections of approximately  on loans which had previously been fully reserved 
based on the above  the company s net loss for fiscal was  a increase over fiscal s net loss of  liquidity and capital resources as of july  the company had working capital of a p p roximately  total cash  cash equivalents and marketable securities were approximately  an increase of  compared to the company s position at july  the increase in the company s cash  cash equivalents and marketable securities in was primarily due to the receipt of  in proceeds from the sale of common stock and warrants in connection with the elan affiliate purchase   in proceeds from the sale of  shares of common stock to two institutional investors in april and  from elan to reimburse the company for certain research and development costs  partially offset by cash used to fund operations in fiscal elan and the company finalized the terms and provisions of the elan joint venture on september  in connection with the elan joint venture  elan has provided  to the jv company of which  has been paid to the company 
the remaining  will be applied by the jv company primarily for future research and development expenses 
after expenditure of such  emisphere will be responsible for one half of the jv company s cash needs upon the jv company s request 
the company and elan are sharing the financial benefits and expense obligations of the elan joint venture on a basis and they have equal representation on the board of directors of the jv company 
see business collaboration agreements 
the company expects to incur substantial research and development expenses associated with the development of the company s oral drug delivery system 
as a result of the ongoing research and development efforts of the company  management believes that the company will continue to incur operating losses and that  potentially  such losses could increase 
the company expects to need substantial resources to continue its research and development efforts 
under present operating assumptions  the company expects that cash  cash equivalents and marketable securities will be adequate to meet its liquidity and capital requirements through the second quarter of fiscal thereafter  the company would need to seek additional funds  primarily in the public and private equity markets  and to the extent necessary and available  through debt financing 
the company has no firm agreements with respect to any additional financing and there can be no assurance that the company would be able to obtain adequate funds on acceptable terms 
if adequate funds were not available  the company would be required to delay  scale back  or eliminate one or more of its research or development programs  or obtain funds  if available  through arrangements with collaborative partners or others that may require the company to relinquish rights to certain of its technologies  product candidates  or products that the company would not otherwise relinquish 
the company does not maintain any credit lines with financial institutions 
impact of the adoption of recently issued accounting standards the financial accounting standards board issued statement of financial accounting standards no 
 accounting for the impairment of long lived assets and long lived assets to be disposed of sfas in march sfas requires companies to review t h e i r long lived assets and certain identifiable intangibles collectively  long lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of a long lived asset may not be recoverable 
impairment is measured using the lower of a long lived asset s book value or fair value  as defined 
the company is not required to adopt the provisions of sfas until the beginning of the fiscal year ending july  the company believes that  based upon current operations and prospects  the future adoption of sfas will not have a material impact on the company s financial position or results of operations 
the financial accounting standards board issued statement of financial accounting standards no 
 accounting for stock based compensation sfas in october sfas requires companies to estimate the fair value of common stock  stock options  or other equity instruments equity instruments issued to employees using pricing models which take into account various factors such as current price of the common stock  volatility and expected life of the equity instrument 
sfas permits companies to either provide pro forma note disclosure or adjust operating results for the amortization of the estimated value of the equity instrument  as compensation expense  over the vesting period of the equity instrument 
the company has elected to provide pro forma note disclosure which will appear in its financial statements for the year ending july  and  therefore  there will be no effect on the company s financial position or results of operations 

